Retatrutide 0.5 mL Injection Volume Studies
Yes, there are multiple published studies evaluating retatrutide at various doses, including a 0.5 mg dose administered subcutaneously, though the evidence focuses on dosing in milligrams rather than volume (mL) specifically.
Key Clinical Trial Evidence
The primary research on retatrutide comes from phase 2 trials that evaluated multiple dose levels:
Type 2 Diabetes Population
In the phase 2 diabetes trial 1, participants received retatrutide at doses ranging from 0.5 mg to 12 mg administered as once-weekly subcutaneous injections. The 0.5 mg dose showed:
- HbA1c reduction of -0.43% at 24 weeks (not significantly different from placebo)
- Body weight reduction of 3.19% at 36 weeks
- Mild-to-moderate gastrointestinal side effects in 13% of participants
The 0.5 mg dose demonstrated minimal efficacy compared to higher doses, with clinically meaningful effects beginning at 4 mg and above.
Obesity Population
The landmark obesity trial 2 evaluated retatrutide 1 mg, 4 mg, 8 mg, and 12 mg doses over 48 weeks. While this study did not include a 0.5 mg arm, the 1 mg dose (the lowest tested) produced:
- 8.7% weight reduction at 48 weeks
- 92% of participants achieving ≥5% weight loss
- Dose-dependent gastrointestinal adverse events
Clinical Implications
The 0.5 mg dose appears to be subtherapeutic for both diabetes and obesity treatment based on available evidence. The phase 2 data clearly demonstrate a dose-response relationship, with meaningful clinical benefits emerging at 4 mg and higher doses 1, 2.
Regarding Volume vs. Dose
The studies report dosing in milligrams (mg), not milliliters (mL). The actual injection volume depends on the drug concentration in the formulation. According to the FDA drug label 3, specific volume information would be provided in the prescribing information, but the clinical trials focused on dose escalation strategies starting at 2 mg or 4 mg initial doses for the therapeutic ranges (4-12 mg maintenance doses).
Dose Escalation Strategy
The research demonstrates that starting doses of 2 mg with gradual escalation to 4-12 mg provide the optimal balance of efficacy and tolerability 1, 2. Starting at 4 mg without escalation increased gastrointestinal side effects compared to initiating at 2 mg.
Safety Profile at Lower Doses
The 0.5 mg dose showed the most favorable gastrointestinal tolerability profile but lacked therapeutic efficacy 1. This suggests it may serve as a potential starting dose for highly sensitive patients, though this approach was not formally studied in the phase 2 trials.
For clinical practice, the evidence supports using retatrutide at doses of 4 mg or higher for meaningful metabolic benefits, with 8-12 mg doses producing the most robust outcomes for both weight reduction (22.8-24.2% at 48 weeks) and glycemic control 2.